首页> 美国卫生研究院文献>Advances in Pharmacological Sciences >Simple and Robust Analysis of Cefuroxime in Human Plasma by LC-MS/MS: Application to a Bioequivalence Study
【2h】

Simple and Robust Analysis of Cefuroxime in Human Plasma by LC-MS/MS: Application to a Bioequivalence Study

机译:LC-MS / MS对头孢呋辛在人血浆中的简单而稳定的分析:在生物等效性研究中的应用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A simple, robust LC-MS/MS assay for quantifying cefuroxime in human plasma was developed. Cefuroxime and tazobactam, as internal standard (IS), were extracted from human plasma by methanol to precipitate protein. Separation was achieved on a Zorbax SB-Aq (4.6 × 250 mm, 5 μm) column under isocratic conditions. The calibration curve was linear in the concentration range of 0.0525–21.0 μg/mL (r = 0.9998). The accuracy was higher than 90.92%, while the intra- and interday precision were less than 6.26%. The extraction procedure provides recovery ranged from 89.44% to 92.32%, for both analyte and IS. Finally, the method was successfully applied to a bioequivalence study of a single 500 mg dose of cefuroxime axetil in 22 healthy Chinese male subjects under fasting condition. Bioequivalence was determined by calculating 90% Cls for the ratios of C max, AUC0−t, and AUC0−∞ values for the test and reference products, using logarithmic transformed data. The 90% Cls for the ratios of C max (91.4%~104.2%), AUC0−t (97.4%~110.9%), and AUC0−∞ (97.6%~111.1%) values were within the predetermined range. It was concluded that the two formulations (test for capsule, reference for tablet) analyzed were bioequivalent in terms of rate and extent of absorption and the method met the principle of quick and easy clinical analysis.
机译:开发了一种简单,强大的LC-MS / MS测定方法,用于定量测定人血浆中的头孢呋辛。用甲醇从人血浆中提取头孢呋辛和他唑巴坦作为内标(IS),以沉淀蛋白质。在等度条件下在Zorbax SB-Aq(4.6×250μm,5μm)色谱柱上完成分离。在0.0525–21.0μg / mL的浓度范围内,校准曲线呈线性(r = 0.9998)。精度高于90.92%,而日内和日间精度均低于6.26%。对于分析物和IS,萃取程序可提供89.44%至92.32%的回收率。最终,该方法成功地用于空腹条件下在22名健康的中国男性受试者中单次500μmg剂量的头孢呋辛酯的生物等效性研究。使用对数转换的数据,通过计算测试和参考产品的C max,AUC0-t和AUC0-∞值的比率计算90%Cls,确定生物等效性。 C max(91.4%〜104.2%),AUC0-t(97.4%〜110.9%)和AUC0-∞(97.6%〜111.1%)的比值的90%Cls在预定范围内。结论是,所分析的两种制剂(胶囊试验,片剂参考)在吸收速率和吸收程度方面具有生物等效性,并且该方法符合快速简便的临床分析原则。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号